Phase II study of bendamustine, rituximab and cytarabine for patients with relapsed or refractory follicular lymphoma or mantle cell lymphoma - GHSG-BRAC

Gifu University Hospital0 个研究点目标入组 13 人开始时间: 2013年1月17日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1) Patients are pregnant or lactating women. Patients (<1 year after menopause without surgical infertility) can not or will not use birth control during the treatment. 2) Patients have active other malignant diseases including simultaneous cancer and disease free state within 5 years after treatment for other cancer except curable intramural cancer by local treatment. 3) Patients have mental disease or disorder with difficulty in participating in the clinical trial. 4) HIV antibody positive, HBs antigen positive, HCV antibody positive 5) Patients have much tumor cell in peripheral blood (>=25,000/mm3). 6) Patients received allogeneic hematopoietic stem cell transplant. 7) Patients have interstitial lung disease or fibroid lung. 8) Patients have CNS invasion. 9) Patients are inappropriate for rituximab treatment. 10) Patients have severe allergic symptoms. 11) Inadequate for clinical trial entry by the attending physicians.

发起方

Gifu University Hospital